Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-9839 in advanced solid tumors
NCT05836948Phase 1Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- May 2023
- Primary completion
- May 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-9839 in solid tumor (advanced stage), sponsored by Hengrui Therapeutics. Primary endpoints: Maximum Tolerated Dose or Maximum Administered Dose at 4 weeks, Recommended Phase 2 Dose and 1 more. Started May 2023; status: recruiting.
02
Drugs
SHR-9839
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05836948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05836948.